Wenlafaksyna: interakcje

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Amfetamina, Ostrzeżenia i środki ostrożności)

Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (etykieta leku Amiodaron, Ostrzeżenia i środki ostrożności)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

In addition, do not start Venlafaxine Extended Release Tablets in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 ). (etykieta leku Wenlafaksyna, Przeciwwskazania)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Buprenorfina, Interakcje z innymi lekami)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Buprenorfina + nalokson, Interakcje z innymi lekami)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Butalbital + kwas acetylosalicylowy + kofeina + kodeina, Interakcje z innymi lekami)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Butalbital + paracetamol + kofeina + kodeina, Interakcje z innymi lekami)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Butorfanol, Środki ostrożności)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (etykieta leku Cyprofloksacyna, Ostrzeżenia i środki ostrożności)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (etykieta leku Deksamfetamina, Interakcje z innymi lekami)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (etykieta leku Dofetylid, Ostrzeżenia)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

…(12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone • QTc interval >500 ms or… (etykieta leku Dronedaron, Przeciwwskazania)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Łączenie dziurawca z lekami przeciwdepresyjnymi i innymi lekami serotoninergicznymi zwiększa ryzyko zespołu serotoninowego. (NCCIH, St. John's Wort)

Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (etykieta leku Edoksaban, Interakcje z innymi lekami)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (etykieta leku Emtrycytabina + rylpiwiryna + tenofowir, Ostrzeżenia i środki ostrożności)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Fentanyl, Ostrzeżenia i środki ostrożności)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (etykieta leku Flukonazol, Przeciwwskazania)

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (etykieta leku Flumazenil, Ostrzeżenie w ramce)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (etykieta leku Fosfomycyna, Interakcje z innymi lekami)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (etykieta leku Foskarnet, Interakcje z innymi lekami)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon, Interakcje z innymi lekami)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon + chlorfenamina, Interakcje z innymi lekami)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydrokodon + homatropina, Interakcje z innymi lekami)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Hydrokodon + ibuprofen, Środki ostrożności)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Hydrokodon + paracetamol, Środki ostrożności)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Hydromorfon, Interakcje z innymi lekami)

Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (etykieta leku Iloperydon, Interakcje z innymi lekami)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etykieta leku Iwabradyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (etykieta leku Wenlafaksyna, Przeciwwskazania)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Kodeina, Interakcje z innymi lekami)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (etykieta leku Lewofloksacyna, Ostrzeżenia i środki ostrożności)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Leworfanol, Środki ostrożności)

In addition, do not start Venlafaxine Extended Release Tablets in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 ). (etykieta leku Wenlafaksyna, Przeciwwskazania)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Lisdeksamfetamina, Ostrzeżenia i środki ostrożności)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (etykieta leku Lopinawir + rytonawir, Ostrzeżenia i środki ostrożności)

LOREEV XR should not be used in such patients without adequate antidepressant therapy. (etykieta leku Lorazepam, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Metadon, Ostrzeżenia i środki ostrożności)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (etykieta leku Metaksalon, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etykieta leku Metamfetamina, Ostrzeżenia i środki ostrożności)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Morfina, Interakcje z innymi lekami)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (etykieta leku Oksaliplatyna, Interakcje z innymi lekami)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (etykieta leku Oksykodon, Interakcje z innymi lekami)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Oksymorfon, Interakcje z innymi lekami)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Olicerydyna, Interakcje z innymi lekami)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Paracetamol + kodeina, Środki ostrożności)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etykieta leku Pentazocyna + nalokson, Środki ostrożności)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (etykieta leku Pimozyd, Przeciwwskazania)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (etykieta leku Pitolisant, Ostrzeżenia i środki ostrożności)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etykieta leku Pokrzyk wilcza jagoda (belladonna) + opium, Interakcje z innymi lekami)

…prolong, or intensify the sedative action of other central-nervous-system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. (etykieta leku Prometazyna, Interakcje z innymi lekami)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etykieta leku Prometazyna + kodeina, Interakcje z innymi lekami)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (etykieta leku Propafenon, Ostrzeżenia i środki ostrożności)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (etykieta leku Wenlafaksyna, Przeciwwskazania)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etykieta leku Remifentanyl, Ostrzeżenia i środki ostrożności)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome and MAOIs: Do not use MAOI’s intended to treat psychiatric disorders with Venlafaxine Extended Release Tablets or within 7 days of stopping treatment with Venlafaxine Extended Release Tablets. (etykieta leku Wenlafaksyna, Przeciwwskazania)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Certain conditions may increase the risk for torsade de pointes or sudden death such as (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [see Warnings and Precautions ( 5.8 ), Clinical Pharmacology (12.2) ]. (etykieta leku Tetrabenazyna, Interakcje z innymi lekami)

CONTRAINDICATIONS Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. (etykieta leku Tiorydazyna, Przeciwwskazania)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (etykieta leku Vepdegestrant, Ostrzeżenia i środki ostrożności)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

Anyone considering the use of Venlafaxine Extended Release Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (etykieta leku Wenlafaksyna, Ostrzeżenie w ramce)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

…drugs, ziprasidone is contraindicated: • in patients with a known history of QT prolongation (including congenital long QT syndrome) • in patients with recent acute myocardial infarction • in patients with uncompensated heart failure Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. (etykieta leku Zyprazydon, Przeciwwskazania)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (etykieta leku Adrenalina, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (etykieta leku Arformoterol, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (etykieta leku Artykaina + adrenalina, Interakcje z innymi lekami)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (etykieta leku Brymonidyna, Interakcje z innymi lekami)

Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (etykieta leku Brymonidyna + tymolol, Interakcje z innymi lekami)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etykieta leku Budezonid + formoterol, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (etykieta leku Bupiwakaina, Ostrzeżenia i środki ostrożności)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (etykieta leku Bupiwakaina + adrenalina, Ostrzeżenia i środki ostrożności)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (etykieta leku Chloroprokaina, Środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Daridoreksant, Ostrzeżenia i środki ostrożności)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Desfluran, Ostrzeżenia i środki ostrożności)

…that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin… (etykieta leku Desmopresyna, Interakcje z innymi lekami)

Diazepam Under steady-state conditions for venlafaxine administered at 150 mg/day, a single 10 mg dose of diazepam did not appear to affect the pharmacokinetics of either venlafaxine or ODV in 18 healthy male subjects. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (etykieta leku Dicykloweryna, Interakcje z innymi lekami)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (etykieta leku Dronabinol, Ostrzeżenia i środki ostrożności)

…cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs… (etykieta leku Droperydol, Ostrzeżenia)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (etykieta leku Erybulina, Ostrzeżenia i środki ostrożności)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (etykieta leku Eszopiklon, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (etykieta leku Fenylefryna, Interakcje z innymi lekami)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (etykieta leku Fenytoina, Interakcje z innymi lekami)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (etykieta leku Fizostygmina, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etykieta leku Flutykazon + salmeterol, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (etykieta leku Formoterol, Interakcje z innymi lekami)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (etykieta leku Fosfenytoina, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etykieta leku Gefitynib, Interakcje z innymi lekami)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (etykieta leku Glikopironium, Interakcje z innymi lekami)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Goserelina, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Haloperidol: Increase in Haloperidol AUC and C max . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (etykieta leku Ipratropium + salbutamol, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Izofluran, Ostrzeżenia i środki ostrożności)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (etykieta leku Izoprenalina, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (etykieta leku Karbidopa + lewodopa + entakapon, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously. (etykieta leku Karyzoprodol, Ostrzeżenia i środki ostrożności)

Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (etykieta leku Klonazepam, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etykieta leku Klopidogrel, Interakcje z innymi lekami)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (etykieta leku Klorazepan, Interakcje z innymi lekami)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (etykieta leku Kokaina, Interakcje z innymi lekami)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. (etykieta leku Kwetiapina, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

TYKERB may prolong the QT interval in some patients. (etykieta leku Lapatynib, Ostrzeżenia i środki ostrożności)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etykieta leku Lemboreksant, Ostrzeżenia i środki ostrożności)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Leuprorelina, Ostrzeżenia i środki ostrożności)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (etykieta leku Lewosalbutamol, Interakcje z innymi lekami)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (etykieta leku Lewotyroksyna, Interakcje z innymi lekami)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (etykieta leku Lidokaina, Interakcje z innymi lekami)

…Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result… (etykieta leku Lidokaina + adrenalina, Ostrzeżenia i środki ostrożności)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (etykieta leku Liotyronina, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (etykieta leku Lumateperon, Ostrzeżenia i środki ostrożności)

Activation of Mania/Hypomania Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. (etykieta leku Lurazydon, Ostrzeżenia i środki ostrożności)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (etykieta leku Meflochina, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (etykieta leku Mepiwakaina, Ostrzeżenia)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Caution should be exercised with co-administration of venlafaxine and metoprolol. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Caution should be exercised with co-administration of venlafaxine and metoprolol. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (etykieta leku Metronidazol, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (etykieta leku Metyloskopolamina, Interakcje z innymi lekami)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (etykieta leku Moksyfloksacyna, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and… (etykieta leku Oksybat sodu, Ostrzeżenia i środki ostrożności)

Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.6 and 2.7 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 ) . ] 7.10 Other Serotonergic Drugs The concomitant use of serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

…combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. (etykieta leku Paliperydon, Ostrzeżenia i środki ostrożności)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etykieta leku Pasyreotyd, Interakcje z innymi lekami)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (etykieta leku Ponesimod, Interakcje z innymi lekami)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (etykieta leku Prylokaina + adrenalina, Interakcje z innymi lekami)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (etykieta leku Prymachina, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (etykieta leku Rokuronium, Ostrzeżenia i środki ostrożności)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

…5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25 mg) was… (etykieta leku Ryfampicyna, Interakcje z innymi lekami)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (etykieta leku Ryfapentyna, Interakcje z innymi lekami)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (etykieta leku Rylpiwiryna, Ostrzeżenia i środki ostrożności)

Risperidone - Venlafaxine administered under steady-state conditions at 150 mg/day slightly inhibited the CYP2D6-mediated metabolism of risperidone (administered as a single 1 mg oral dose) to its active metabolite, 9-hydroxyrisperidone, resulting in an approximate 32% increase in risperidone AUC. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etykieta leku Salbutamol, Interakcje z innymi lekami)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etykieta leku Salmeterol, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Sewofluran, Ostrzeżenia)

Concomitant use of other drugs that cause central nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [see Drug Interactions ( 7.1 )] . (etykieta leku Skopolamina, Ostrzeżenia i środki ostrożności)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etykieta leku Sorafenib, Ostrzeżenia i środki ostrożności)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (etykieta leku Sotalol, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (etykieta leku Sulfametoksazol + trimetoprim, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etykieta leku Sunitynib, Interakcje z innymi lekami)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

The benzodiazepines, including temazepam, produce additive CNS-depressant effects when co-administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. (etykieta leku Temazepam, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (etykieta leku Terbutalina, Środki ostrożności)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

…quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (etykieta leku Toremifen, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Tryptorelina, Ostrzeżenia i środki ostrożności)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etykieta leku Umeklidynium + wilanterol, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Patients receiving warfarin therapy should be carefully monitored when Venlafaxine Extended-Release Tablets are initiated or discontinued [see Warnings and Precautions ( 5.13 )] . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (etykieta leku Wazopresyna, Interakcje z innymi lekami)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Concomitant use of CYP3A4 inhibitors and venlafaxine may increase levels of venlafaxine and ODV. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine. (etykieta leku Zaleplon, Interakcje z innymi lekami)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etykieta leku Zasadowy cytrynian bizmutu + metronidazol + tetracyklina, Ostrzeżenia i środki ostrożności)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use [see Drug Interactions (7.1) ] . (etykieta leku Zolpidem, Ostrzeżenia i środki ostrożności)

Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

This finding was confirmed in vivo by clinical drug interaction studies in which venlafaxine did not inhibit the metabolism of several CYP3A4 substrates, including alprazolam, diazepam, and terfenadine. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRI’s (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRI’s (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood,… (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants. (etykieta leku Benzatropina, Ostrzeżenia)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (etykieta leku Brekspiprazol, Ostrzeżenia i środki ostrożności)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (etykieta leku Diwalproeks (walproinian), Interakcje z innymi lekami)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

…quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone,… (etykieta leku Hydroksyzyna, Środki ostrożności)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations. (etykieta leku Karbidopa, Interakcje z innymi lekami)

…placebo-controlled trials of adult patients with major depressive disorder, the proportion of patients with shifts in fasting glucose from normal (<100 mg/dL) to high (≥126 mg/dL) was greatest in the VRAYLAR 3 mg per day + antidepressant therapy arm (3.2%) compared with those taking VRAYLAR 1.5 mg per day + antidepressant therapy (2%) or those placebo-treated (1.3%). (etykieta leku Kariprazyna, Ostrzeżenia i środki ostrożności)

Postmarketing Spontaneous Drug Interaction Reports There have been reports of elevated clozapine levels that were temporally associated with adverse reactions, including seizures, following the addition of venlafaxine. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

This finding was confirmed in vivo by a clinical drug interaction study in which venlafaxine did not inhibit the metabolism of caffeine, a CYP1A2 substrate. (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (etykieta leku Kwas walproinowy, Interakcje z innymi lekami)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (etykieta leku Lowastatyna, Ostrzeżenia)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (etykieta leku Perfenazyna, Interakcje z innymi lekami)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (etykieta leku Tiagabina, Ostrzeżenia)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (etykieta leku Triheksyfenidyl, Interakcje z innymi lekami)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRI’s (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRI’s (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood,… (etykieta leku Wenlafaksyna, Ostrzeżenia i środki ostrożności)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

CYP1A2 Venlafaxine did not inhibit CYP1A2 in vitro . (etykieta leku Wenlafaksyna, Interakcje z innymi lekami)

In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin), or CYP3A4 (e.g., dextromethorphan) when coadministered with ABILIFY MAINTENA. (etykieta leku Arypiprazol, Interakcje z innymi lekami)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (etykieta leku Entakapon, Środki ostrożności)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (etykieta leku Ropinirol, Interakcje z innymi lekami)